| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | CKR5; CCR-5; CD195; CKR-5; CCCKR5; CMKBR5; IDDM22; CC-CKR-5 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CCR5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCR5抗体的3篇代表性文献及其摘要：
---
1. **文献名称**: *CCR5 blockade with leronlimab in patients with multidrug-resistant HIV-1: a phase 2 study*
**作者**: Jacobson JM, et al.
**摘要**: 该研究报道了人源化CCR5单克隆抗体leronlimab(PRO 140)在治疗多药耐药HIV-1感染患者的II期临床试验结果。结果显示，每周皮下注射leronlimab可显著降低病毒载量并维持CD4+ T细胞水平，证实其作为长效HIV疗法的潜力。
---
2. **文献名称**: *Targeting CCR5 in cancer immunotherapy: a promising combination strategy?*
**作者**: Halama N, et al.
**摘要**: 本文综述了CCR5在肿瘤微环境中的作用，指出CCR5高表达与免疫抑制性细胞(如Treg和MDSCs)浸润相关。实验表明，抗CCR5抗体联合PD-1抑制剂可增强抗肿瘤免疫反应，为癌症免疫治疗提供了新策略。
---
3. **文献名称**: *CCR5 as a therapeutic target in inflammatory diseases*
**作者**: Oppermann M.
**摘要**: 该研究探讨了CCR5在类风湿性关节炎、多发性硬化等炎症疾病中的病理机制，并评估了抗CCR5抗体的治疗效果。临床前模型显示，阻断CCR5可减少炎症细胞迁移和组织损伤，提示其在慢性炎症疾病中的治疗潜力。
---
这些文献涵盖了CCR5抗体在HIV治疗、癌症免疫治疗和炎症疾病中的关键应用方向。
CCR5. a chemokine receptor predominantly expressed on immune cells like T lymphocytes and macrophages, plays a pivotal role in inflammatory responses and cell migration. It gained prominence due to its co-receptor function in HIV-1 entry, where the virus binds to CD4 and CCR5 to infect host cells. The discovery of the CCR5-Δ32 mutation, which confers natural resistance to HIV in homozygous individuals, spurred interest in targeting CCR5 therapeutically.
CCR5 antibodies are monoclonal antibodies designed to block this receptor. By binding to CCR5. they inhibit HIV entry, disrupt chemokine-mediated signaling, and modulate immune cell trafficking. Notable examples include leronlimab (PRO 140), a humanized IgG4 antibody tested in HIV and COVID-19 trials. Beyond virology, CCR5 is implicated in cancer metastasis, autoimmune diseases, and graft-versus-host disease (GVHD), expanding the antibody’s potential applications.
While early clinical studies demonstrated reduced viral loads in HIV patients, challenges like viral resistance and variable efficacy persist. Emerging research explores CCR5 antibodies in combination therapies or as adjuvants in cancer immunotherapy to counteract immunosuppressive tumor microenvironments. However, safety concerns, including unintended immunosuppression, require careful evaluation. Overall, CCR5 antibodies represent a versatile tool bridging virology, oncology, and immunology, though further optimization is needed for broad clinical adoption.
×
